International Medical Sales Surge 43% as GMP Certified Producer Hits Global Growth Phase
As international medical cannabis demand surges, a shift in global regulatory landscapes is creating a distinct advantage for producers with pharmaceutical-grade infrastructure. While the domestic Canadian market has faced persistent headwinds from pricing compression and tax burdens, the opening of major European and South American markets has redirected the sector’s growth trajectory toward higher-margin export channels. Germany's patient market has grown significantly following regulatory changes that simplified prescribing, while Canadian exports have seen a promising year-on-year increase as licensed producers with the right certifications found buyers across Europe, Australia, and Brazil. The companies now leading the space are those that moved beyond simple cultivation to secure the complex GMP certifications required to enter licensed pharmacy networks, a strategy validated today by a 43% surge in international revenue from a leading Canadian manufacturer.
MediPharm Labs (TSX: LABS)(OTCQB: MEDIF) reported its full year and Q4 2025 results, highlighted by revenue of $45.1M, up 8% from 2024. While the headline number is steady, international medical cannabis revenue reached $25.2M for the year, representing 43% growth over the prior year and crossing the threshold to represent more than 50% of total company revenue. This shift is critical as domestic sales have been muted by pricing pressure and margin erosion across the broader industry.
Q4 revenue came in at $11.1M (compared to $12.0M in Q4 2024), reflecting timing and product mix differences rather than a structural decline. However, international medical cannabis contributed $6.1M in Q4, representing 55% of quarterly revenue. Gross profit for 2025 was $14.0M, representing a 31% margin, which compares positively to Q4 2025’s margin of 35%. This suggests the product mix shift toward international sales is having a tangible positive effect on per-unit economics.
MediPharm ended Q4 with $10.8M in cash, up $0.2M from Q3, with the company current on excise duties and trade payables. The company remains virtually debt-free and owns two production facilities outright, with a combined appraised value of more than $15M. In a sector where balance sheet stress has forced multiple Canadian operators into dilutive financings or restructurings, the company's position is genuinely differentiated.
What separates the firm from most producers attempting to access international markets is the regulatory credential stack it has assembled. The company holds a Health Canada Pharmaceutical Drug Establishment License with a commercial-scale GMP license for the extraction of multiple natural cannabinoids. It also holds EU-GMP certification, ANVISA GMP certification from Brazil, and TGA compliance in Australia. This combination opens doors that are closed to producers who lack downstream pharmaceutical-grade processing infrastructure.
The market opportunity is significant. Germany's regulatory shift has driven robust patient growth, and the country now represents the largest medical cannabis market outside North America. France is in the early stages of commercial rollout, and Brazil, where MediPharm made its first delivery under sanitary authorization in 2025, is one of the largest potential markets in the world by population. New Zealand approvals are secured with planned launches in 2026. The international expansion roadmap is built around markets that require pharmaceutical-grade supply where GMP certification is a non-negotiable requirement.
Despite the positivity, shares of LABS are unchanged on the back of today’s results. With Brazil and France channels established, New Zealand launches planned for 2026, and a balance sheet that does not require external capital to fund the next phase, the company has a strong setup heading into the remainder of 2026.
Copyright © 2026 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
View more of this article on AllPennyStocks.com.
About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.
Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.
AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Contact:
AllPennyStocks.com Media, Inc.
Email: ads@allpennystocks.com
Phone: (800) 558-4560 Ext: 101
